



Lysantum® - Human Platelet Lysate you can rely on

Lysantum® provides Human Platelet Lysate (hPL), developed to meet the highest standards in research, translational science, and clinical manufacturing.

Our xeno-free, human-derived cell culture supplement offers a superior alternative to Fetal Bovine Serum (FBS), delivering enhanced bio-compatibility, regulatory alignment, and consistent, high-performance cell expansion.



Advancing cell culture.
Accelerating regenerative medicine.



Belgian
Red Cross

What is Human Platelet Lysate?

Human Platelet Lysate (hPL) is a human-derived, xeno-free cell culture supplement developed as a safe and high-performance alternative to Fetal Bovine Serum (FBS). Rich in platelet-derived growth factors and cytokines, it promotes robust cell proliferation while maintaining differentiation potential. Thanks to standardized production, hPL delivers greater batch consistency and reduced variability compared to FBS. The result is more reliable cell expansion with higher biosafety — a dependable solution for researchers and biotech developers seeking reproducibility and safety.


Introducing Lysantum®

Lysantum® hPL is manufactured exclusively from **surplus platelets donated by healthy, consenting volunteers** and sourced through qualified European blood establishments.

Lysantum® eliminates xenogenic risks, reduces zoonotic transmission concerns, and prevents immunization against animal-derived proteins.

Its human origin and manufacturing in accordance with EU Good Manufacturing Practice (GMP) requirements, makes it ideally suited for advanced therapies and clinical manufacturing.


Our hPL is particularly well suited for the expansion of a **broad range of cell types**, including mesenchymal stromal cells (MSCs), T-cells, dermal fibroblasts, keratinocytes and endothelial cells, delivering high performance and reproducible results in both research and translational settings.




Why choose Lysantum powered by Belgian Red Cross ?

Researchers and biotech companies are increasingly facing challenges in sourcing reliable tissue culture supplements, often dealing with quality variability and limited availability. Belgian Red Cross is well positioned to fill this need. With decades of experience in processing blood-derived products, we offer an innovative and standardized approach that ensures consistent quality and reliable supply.

Verified batch-to-batch consistency



Proven scalability through standardized hPL manufacturing across three countries



Reliable & scalable supply



Closed system production



Patented technology



Low batch-to-batch variability



Time- and cost-efficient



Xeno-free



European donors

Manufacturing excellence

Our state-of-the-art facilities ensure the highest quality standards in every batch.



Full control & traceability

Belgian Red Cross controls the **full hPL process** – from donor collection to final product – ensuring reliable supply, strict handling, traceability, and respect for donor consent.



Standardised production process

Production occurs in a cleanroom in a **fully closed system**, avoiding air exposure and delivering far greater consistency than FBS. Its low batch-to-batch variability is achieved through transfusion-grade standardization and donor pooling.



Proprietary process

A proprietary process removes platelet residues and reduces fibrinogen, **eliminating the need for heparin** while preserving high growth-factor content.



Pathogen inactivated

All donations come from voluntary, non-remunerated European donors, are extensively tested and pathogen-inactivated, and are supported by full batch documentation, including Certificates of Analysis.

Lysantum® Product line



			
Research Grade	Clinical Grade	Research Grade	Clinical Grade
Low Ca ²⁺ media such as DMEM/F-12, RPMI-1640, IMDM, Ham's F-12, TexMACS, ...		Most media such as DMEM, αMEM, DMEM/F-12, IMDM, Ham's F-12, TexMACS, ...	
European origin – Pathogen inactivated – no heparin required			



Request your free 30 ml evaluation sample
Experience the performance difference in
your own lab
www.lysantum.com/samples

About us

The Belgian Red Cross is an independent humanitarian organization founded in 1864 and part of the International Red Cross and Red Crescent Movement, operating nationwide to provide emergency relief, disaster response, first aid training, and social support.

In addition to its public health mission, it collects and processes blood-derived products including Human Platelet Lysate (hPL), a xeno-free cell culture supplement used in research, cell therapy, and regenerative medicine to support animal-free and innovative research strategies.

Contact us

Transfusion Research Center
Ottergemsesteenweg 413
9000 Gent
Belgium

☎ +32 9 244 56 58
🌐 sales.hpl@rodekruis.be
✉ www.lysantum.com
🌐 [linkedin.com/company/lysantum](https://www.linkedin.com/company/lysantum)



Check out our Lysantum video
www.lysantum.com

Selected publications referencing our HPL

Delabie W, Vandewalle V, Seghers S, De Bleser D, Vandekerckhove P, Feys HB. *Comparison of culture media supplements identifies serum components in self-reported serum-free preparations.* Stem Cell Res Ther 2025.

Delabie W, Boretti G, Groot SA, Ardanary D, Sigurjónsson O, Klei TRL, Vandekerckhove P, Feys HB. *Human platelet lysate standardization across three independent European blood establishments.* Stem Cell Res Ther 2025.

Delabie W, De Bleser D, Vandewalle V, De Prest M, Vandekerckhove P, Compennolle V, Feys HB. *The impact of amotosalen photochemical pathogen inactivation on human platelet lysate.* Curr Stem Cell Res Ther 2024.

De Korte D, Delabie W, Feys H, Klei T, Larsen R, Sigurjónsson Ó, Sousa AP. *Towards standardized human platelet lysate production in Europe: an initiative of the European Blood Alliance.* Vox Sang 2024.

Delabie W, De Bleser D, Vandewalle V, Vandekerckhove P, Compennolle V, Feys H. *Single step method for high yield human platelet lysate production.* Transfusion 2023.